Abstract Number: 1056 • 2013 ACR/ARHP Annual Meeting
Adherence To Methotrexate Therapy Among Patients With Rheumatoid Arthritis In Denmark: A Registry Based Cohort Study
Background/Purpose: Conflicting data have been presented on patient compliance with methotrexate (MTX) prescription. A Danish study found a mean period of 12.3% of the prescribed…Abstract Number: 1057 • 2013 ACR/ARHP Annual Meeting
Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States
Background/Purpose: Current ACR guidelines call for treatment of rheumatoid arthritis (RA) with non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs). The National Quality Forum has…Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…Abstract Number: 1060 • 2013 ACR/ARHP Annual Meeting
Perinatal Risk Factors For Systemic Lupus: A Register-Based Case-Control Study
Background/Purpose: One’s own fetal environment has been linked to future heart disease, breast cancer, and rheumatoid arthritis. Prior work showed that among older women in…Abstract Number: 1061 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States
Background/Purpose: The rash of discoid lupus erythematosus (DLE) has been reported in 10-25% of patients with systemic lupus erythematosus (SLE). Prior reports suggest that DLE…Abstract Number: 1062 • 2013 ACR/ARHP Annual Meeting
The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus
The Brief Index of Lupus Damage as a Predictor of Mortality in a Cohort of Patients with Systemic Lupus Erythematosus Background/Purpose: To examine whether a…Abstract Number: 1063 • 2013 ACR/ARHP Annual Meeting
The Influence Of Socioeconomic and Race In Damage Score In Patients With Systemic Lupus Erythematosus
Background/Purpose: The association between socioeconomic status and damage in Systemic lupus erythematosus patients is confounded by the influence of race in various previous studies. The…Abstract Number: 1064 • 2013 ACR/ARHP Annual Meeting
Trends In Hospitalizations Due To Organ Damage In Patients With Systemic Lupus Erythematosus In Canada, 2006-2010
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect multiple organs in the body, including the heart, kidney and lung, leading to…Abstract Number: 1065 • 2013 ACR/ARHP Annual Meeting
Acute Myocardial Infarction Variation Among U.S. Medicaid Recipients With Systemic Lupus Erythematosus By Race and Ethnicity, 2000-2006
Background/Purpose: SLE patients have elevated rates of acute myocardial infarctions (MI), but the sociodemographic groups that are most affected have not been well studied. We…Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting
Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…Abstract Number: 1067 • 2013 ACR/ARHP Annual Meeting
Incidence and Prevalence Of Systemic Lupus Erythematosus: A 2010 Nation-Wide Population-Based Study Using French National Administrative Databases
Background/Purpose: To date, only a small number of studies have examined the epidemiology of systemic lupus erythematosus (SLE) on a nation-wide basis. These studies were…Abstract Number: 1069 • 2013 ACR/ARHP Annual Meeting
Racial Differences In Systemic Lupus Erythematosus Patients’ Treatment Preferences: A Two-Site Study
Background/Purpose: Racial disparities in systemic lupus erythematosus (SLE) exist, with African-American (AA) patients experiencing higher lupus damage scores and disease activity than white (WH) patients. …Abstract Number: 1070 • 2013 ACR/ARHP Annual Meeting
Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus
Background/Purpose: Belimumab is a B lymphocyte stimulator-specific inhibitor approved for treatment of systemic lupus erythematosus (SLE). The purpose of the study was to describe medication…Abstract Number: 1071 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data
Background/Purpose: Prevalence estimates of Systemic Lupus Erythematosus (SLE) in the U.S. vary, with numbers ranging from 161,000 (Helmick, 2008) to 1.5 million (Lupus Foundation of…Abstract Number: 1032 • 2013 ACR/ARHP Annual Meeting
Shared Decision-Making In The Choice Of Biologic Medication: The Patient Perspective
Background/Purpose: There has been increasing focus on the importance of patients participating in the treatment decision-making process with their physicians. Previous research has demonstrated that…